Myocardial contrast echocardiography: Role in clinical cardiology.

abstract：:In patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), 25OH-vitamin D (calcidiol) deficiency or insufficiency is a common finding with high prevalence. Numerous epidemiological studies have found an independent association of low levels of calcidiol with increased morbidity and mortality. Wi...

journal_title：Current vascular pharmacology

authors： Brandenburg VM,Kruger T

更新日期：2014-03-01 00:00:00

abstract：:In end-stage renal disease patients, the leading causes of mortality are of cardiovascular (CV) origin. The underlying mechanisms are complex, given that sudden heart failure is more common than acute myocardial infarction. A contributing role of oxidative stress is postulated, which is increased even at early stages ...

journal_title：Current vascular pharmacology

authors： Roumeliotis S,Roumeliotis A,Gorny X,Mertens PR

更新日期：2021-01-01 00:00:00

abstract：:The renin-angiotensin system (RAS) plays an essential role in fluid and electrolyte homeostasis and the regulation of vascular tone; however, dysregulation and over-activation of the RAS lead to the pathogenesis of various cardiovascular diseases. The RAS is closely associated with NADPH oxidase, a major enzymatic sou...

journal_title：Current vascular pharmacology

authors： Honjo T,Yamaoka-Tojo M,Inoue N

更新日期：2011-03-01 00:00:00

abstract：INTRODUCTION:Diabetes mellitus (DM) is one of the most common diseases worldwide. Its adverse effects on several body organs, have made treatment of DM a priority. One of the most serious complications of DM is diabetic nephropathy (DN). OBJECTIVE:The aim of this review is to critically discuss available data on the p...

journal_title：Current vascular pharmacology

authors： Papademetriou V,Alataki S,Stavropoulos K,Papadopoulos C,Bakogiannis K,Tsioufis K

更新日期：2020-01-01 00:00:00

abstract：:Cardiovascular disease (CVD) is among the most major causes of morbidity and mortality worldwide. Great progress has been made in the management of CVD which has been influenced by the use of experimental animal models. These models provided information at cellular and molecular levels and allowed the development of t...

journal_title：Current vascular pharmacology

authors： Haidara MA,Assiri AS,Yassin HZ,Ammar HI,Obradovic MM,Isenovic ER

更新日期：2015-01-01 00:00:00

abstract：:The pathogenesis of obesity, insulin resistance and hypertension begins with an interaction between genetic factors and environmental factors. The search for the underlying genetic basis of these conditions has yielded disappointing results. It is possible that the importance of environmental influences has been under...

journal_title：Current vascular pharmacology

authors： Sharma V,McNeill JH

更新日期：2006-10-01 00:00:00

abstract：:The aim of this review is to present, critically appraise and qualitatively synthesize current evidence on the risk of type 2 diabetes mellitus (T2DM) development during menopause, the management of climacteric symptoms in women with T2DM and the management of T2DM in postmenopausal women. Menopause represents the end...

journal_title：Current vascular pharmacology

authors： Paschou SA,Anagnostis P,Pavlou DI,Vryonidou A,Goulis DG,Lambrinoudaki I

更新日期：2019-01-01 00:00:00

abstract：:Visfatin is highly expressed in adipose tissue (mainly by the stromal cells), but it is also ubiquitously present in most tissues. Visfatin, which plays a role in nicotinamide adenine dinucleotide (NAD) biosynthesis, has been implicated in inflammatory states. Controversial results exist about the expression, circulat...

journal_title：Current vascular pharmacology

authors： Filippatos TD,Randeva HS,Derdemezis CS,Elisaf MS,Mikhailidis DP

更新日期：2010-01-01 00:00:00

abstract：:Epidemiological evidence supports a reduced prevalence of Thoracic Aortic Aneurysm (TAA) and Abdominal Aortic Aneurysm (AAA) in patients with Diabetes (DM). The mechanisms underlying this negative association are unknown. Some studies support that hyperglycemia has effects on the Extracellular Matrix (ECM), resulting ...

journal_title：Current vascular pharmacology

authors： Krizhanovskii C,Franco-Cereceda A

更新日期：2019-01-01 00:00:00

abstract：:Many patients with hypertension will require multiple antihypertensive drugs to achieve blood pressure (BP) control. This double-blind study evaluated the efficacy and safety of aliskiren/amlodipine single-pill combinations (SPCs) in patients with mild-to-moderate hypertension who were non-responsive to aliskiren mono...

journal_title：Current vascular pharmacology

authors： Glorioso N,Thomas M,Troffa C,Argiolas G,Patel S,Baek I,Zhang J

更新日期：2012-11-01 00:00:00

abstract：:Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. The available data suggest that efforts to reduce mortality in the CKD population should be focused on treatment and prevention of, among others, coronary artery disease and congestive heart failure. Accelerated atherosclerosi...

journal_title：Current vascular pharmacology

authors： Franczyk-Skóra B,Gluba A,Banach M,Rozentryt P,Poloński L,Rysz J

更新日期：2013-09-01 00:00:00

abstract：:The recently published Assessment of Survival and Cardiovascular Events (AURORA) trial showed that rosuvastatin (10 mg/d) compared with placebo did not result in a significant reduction in vascular events despite a 43% fall in low density lipoprotein cholesterol (LDL-C) levels in patients with end-stage renal disease ...

journal_title：Current vascular pharmacology

authors： Athyros VG,Tziomalos K,Karagiannis A,Mikhailidis DP

更新日期：2009-07-01 00:00:00

abstract：:High blood pressure (BP) along with smoking habit and lipid disorders are the most important and modifiable risk factors for cardiovascular diseases. However, the prevalence of high BP has grown progressively over time with a progressive increase not only in the absolute number of patients but in the proportion of tho...

journal_title：Current vascular pharmacology

authors： Borghi C

更新日期：2012-11-01 00:00:00

abstract：:High density lipoprotein (HDL) is recognized as the major negative risk factor of cardiovascular disease and number of anti-atherogenic functions has been ascribed to HDL. HDL is an assembly of a neutral lipid core and an outer shell consisting of polar lipids and proteins. It has been defined many different ways base...

journal_title：Current vascular pharmacology

authors： Vaisar T

更新日期：2012-07-01 00:00:00

abstract：:In this issue of Curr Vasc Pharmacol, Pfeiffer et al. [1] and Glorioso et al. [2] report the efficacy and tolerability of aliskiren/amlodipine single-pill combinations (SPCs) in patients with inadequate blood pressure (BP) response to amlodipine or aliskiren monotherapy, respectively. ...

journal_title：Current vascular pharmacology

authors： Katsiki N,Athyros VG,Mikhailidis DP,Karagiannis A

更新日期：2012-11-01 00:00:00

abstract：:In recent years, the development of more effective drugs has provided a better prognosis and an increase in life expectancy for patients at all-stages of cancer. On the other hand, the price for the improving effectiveness of therapies against malignant tumors is the development of severe and potentially life-threaten...

journal_title：Current vascular pharmacology

authors： Perrino C,Schiattarella GG,Magliulo F,Ilardi F,Carotenuto G,Gargiulo G,Serino F,Ferrone M,Scudiero F,Carbone A,Trimarco B,Esposito G

更新日期：2014-01-01 00:00:00

abstract：:This essay focuses on nine important lessons learned during more than thirty years of endothelial research. They include: the danger of hiding behind a word, the confusion generated by abbreviations, the need to define the physiological role of the response studied, the local role of endothelium- dependent responses, ...

journal_title：Current vascular pharmacology

authors： Vanhoutte PM

更新日期：2016-01-01 00:00:00

abstract：:Non-fasting triglycerides are measured at any time within up to 8 h (14 h) after any normal meal, while postprandial triglycerides are measured at a fixed time point within up to 8 h (14 h) of a standardised fat tolerance test. The simplest possible way of evaluating remnant cholesterol is non-fasting/postprandial tot...

journal_title：Current vascular pharmacology

authors： Nordestgaard BG,Freiberg JJ

更新日期：2011-05-01 00:00:00

abstract：:In chronic inflammatory conditions, endothelial cells actively recruit immune cells from the circulation into the underlying tissue and participate in angiogenesis to support the continuous demand for oxygen and nutrients. They do so in response to activation by cytokines and growth factors such as tumour necrosis fac...

journal_title：Current vascular pharmacology

authors： Kułdo JM,Ogawara KI,Werner N,Asgeirsdóttir SA,Kamps JA,Kok RJ,Molema G

更新日期：2005-01-01 00:00:00

abstract：:Cardiovascular failure in sepsis involves a combination of hypovolemia, decreased vascular tone, myocardial depression and microcirculatory alterations. Fluids represent the first line therapeutic intervention, with controversy regarding the type of fluid. Recent data indicate that albumin is safe and might even be be...

journal_title：Current vascular pharmacology

authors： De Backer D,Scolletta S

更新日期：2013-03-01 00:00:00

abstract：INTRODUCTION:Chlamydia pneumoniae was the first pathogen linked with carotid atherosclerotic changes and plaque rupture. Currently, other common pathogens are also under investigation as potential contributors. METHODS:A systematic review of PubMed and Scopus databases was performed. Studies evaluating the infectious ...

journal_title：Current vascular pharmacology

authors： Makris GC,Makris MC,Wilmot VV,Geroulakos G,Falagas ME

更新日期：2010-11-01 00:00:00

abstract：:Arterial stiffness (AS) is considered an independent predictor of cardiovascular disease (CVD) events. Among lipid lowering drugs, statins have a beneficial effect on AS, independent of their hypolipidaemic effect. Based on 3 meta-analyses and other studies, this effect is compound- and doserelated. Potent statins at ...

journal_title：Current vascular pharmacology

authors： Reklou A,Katsiki N,Karagiannis A,Athyros V

更新日期：2020-01-01 00:00:00

abstract：:The vascular endothelium is a monolayer of cells between the vessel lumen and the vascular smooth muscle cells. Nitric oxide (NO) is a soluble gas continuously synthesized from the amino acid L-arginine in endothelial cells by the constitutive calcium-calmodulin-dependent enzyme nitric oxide synthase (NOS). This subst...

journal_title：Current vascular pharmacology

authors： Tousoulis D,Kampoli AM,Tentolouris C,Papageorgiou N,Stefanadis C

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND:Add-on therapy with the Mineralocorticoid-Receptor-Antagonists (MRAs) spironolactone and eplerenone was shown to enhance the cardioprotective action of angiotensinconverting- enzyme-inhibitors (ACEIs), angiotensin-receptor-blockers (ARBs) and/or β-blockers in nondialysis patients with congestive heart failur...

journal_title：Current vascular pharmacology

authors： Georgianos PI,Vaios V,Eleftheriadis T,Zebekakis P,Liakopoulos V

更新日期：2017-01-01 00:00:00

abstract：:Statins are beneficial both in the primary and secondary prevention of atherosclerotic vascular disease and acute events in a broad spectrum of patient subgroups. However, the observed clinical benefit with statin therapy is much greater than expected through the reduction of cholesterol levels alone. Clinical and exp...

journal_title：Current vascular pharmacology

authors： Yildirir A,Müderrisoglu H

更新日期：2004-10-01 00:00:00

abstract：:We evaluated the effects of the glycosaminoglycan sulodexide (SDX; antithrombotic/profibrinolytic drug) on the activity and release of matrix metalloproteinases (MMPs) in human blood. This was a prospective non-randomized study, analyzing by zymography and ELISA the in vitro effects of SDX on pro-enzyme, complexed, an...

journal_title：Current vascular pharmacology

authors： Mannello F,Medda V,Ligi D,Raffetto JD

更新日期：2013-05-01 00:00:00

abstract：BACKGROUND:Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used, having numerous indications. However, despite their therapeutic role, they are associated with serious cardiovascular (CV) adverse events. Objectives-Methods: This review comprising recent observational studies and metaanalyses over the past few...

journal_title：Current vascular pharmacology

authors： Kontogiorgis C,Valikeserlis I,Hadjipavlou-Litina D,Nena E,Constantinidis TC

更新日期：2016-01-01 00:00:00

abstract：:Obesity is a highly prevalent complex trait that raises the risk of other chronic diseases such as type 2 diabetes, certain cancers, sleep apnea, and cardiovascular disease, and shortens lifespan. Clinical intervention studies focused on weight loss and epidemiological studies of obesity indicate that genetic variatio...

journal_title：Current vascular pharmacology

authors： Franks PW,Poveda A

更新日期：2011-07-01 00:00:00

abstract：:Immunosuppressive drugs (ISDs) have a major impact on the development and progression of cardiac allograft vasculopathy (CAV), the main cause of cardiac allograft loss and a leading cause of death beyond the 1st post-transplant year. The influence of ISDs on the development and progression of CAV is complex. In spite ...

journal_title：Current vascular pharmacology

authors： Dandel M,Hetzer R

更新日期：2010-09-01 00:00:00

abstract：:Post-transplant diabetes mellitus (PTDM) and dyslipidaemia are the most common metabolic complications in kidney transplant recipients (KTR). They are associated with a higher risk of lower graft function and survival, as well as an increased risk of cardiovascular disease (CVD). The aim of this review is to provide c...

journal_title：Current vascular pharmacology

authors： Anagnostis P,Paschou SA,Spartalis E,Sarno G,De Rosa P,Muscogiuri G

更新日期：2020-01-01 00:00:00